Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/5/2009

SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2009.

Based upon the Priority Review designation granted by the FDA for Cadence's New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), the company accelerated its commercial readiness activities during the third quarter of 2009. Commenting on the third quarter achievements, Ted Schroeder, President and CEO of Cadence stated, "We are extremely pleased with the progress we have made in building our commercial infrastructure, including the recruitment of a highly experienced commercial leadership team to launch Acetavance, if approved by the FDA."

Financial Results

For the three months ended September 30, 2009, Cadence reported a net loss of $11.4 million, or $0.23 per share, compared to a net loss of $13.7 million, or $0.36 per share, for the same period in 2008. Operating expenses for the three months ended September 30, 2009 decreased $2.4 million to $11.3 million, from the $13.7 million reported for the comparable period in 2008. The decline in operating expenses during the current year was primarily the result of a reduction in research and development costs as the company completed its clinical development program for Acetavance in early 2009 and submitted an NDA for this product candidate in May 2009. Further, in March 2009, the company discontinued the development program for its omiganan product candidate. Partially offsetting this reduction is an increase in sales and marketing expenses as the company focused significant resources on establishing its com
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
3. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
4. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
9. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
(Date:10/19/2014)... 2014 The leading review website, ... ) and GreenGeeks are the best Dedicated Server ... those who want to buy high quality hosting ... The IT manager of Top10BestSEOHosting.com says, “We believe ... suppliers for everyone. A lot of the global ...
(Date:10/19/2014)... 20, 2014 This report provides ... Seizure, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ... special features on late-stage and discontinued projects. , ...
(Date:10/19/2014)... October 20, 2014 Recently, Fancyflyingfox.com, an ... occasion clothes, has announced its latest designs of 2014 ... all the new elegant outfits are offered with big ... an order before October 30 can enjoy this special ... great marketing strategies, it has become one of the ...
(Date:10/19/2014)... Stephen T. Greenberg, M.D., with offices in ... 10th consecutive year as one of Long Island’s best cosmetic ... been nominated as the best provider for Botox injections. Glisten, ... Day Spa and best Laser Treatment center on Long Island.* ... can vote for the contest once per day, per IP ...
Breaking Medicine News(10 mins):Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2
... Corporation,(Nasdaq: DRAD ), a leading provider of ... hospitals and imaging centers, today,announced that its board ... and member of the audit and governance committees, ... has served on Digirad,s board of directors since ...
... by a government intent on promoting innovation and fuelled ... returning from abroad, Chinas health biotech industry only needs ... global force in the production of therapies and medicines ... in a new study. , Long considered a skillful ...
... YORK, Jan. 7 The American Stock Exchange ... the common,stock (the "Securities") of Samaritan Pharmaceuticals, Inc. ... on Form 25 to strike the Securities,from listing ... The,delisting will become effective on January 17, 2008 ...
... out of 10 shoppers in the Northeast are more, worried about ... ... just one year ago, DEERFIELD, Ill., Jan. 7 Consumers ... comes to,the safety of food purchased in their stores, according to a ...
... the U.S. Department of Energy,s Brookhaven National Laboratory and colleagues ... to sunlight - namely the production of vitamin D, which ... and other diseases - may outweigh the risk of developing ... will be published online in the Proceedings of the National ...
... adds to growing body of evidence thats finds no ... News) -- Adding to a growing body of evidence ... a new study finds no proof that incidences of ... stopped using a mercury-based preservative in their products. , ...
Cached Medicine News:Health News:Digirad Corporation Board of Directors Appoints R. King Nelson Chairman 2Health News:Digirad Corporation Board of Directors Appoints R. King Nelson Chairman 3Health News:Digirad Corporation Board of Directors Appoints R. King Nelson Chairman 4Health News:China's biotech industry: An Asian dragon is growing 2Health News:China's biotech industry: An Asian dragon is growing 3Health News:China's biotech industry: An Asian dragon is growing 4Health News:China's biotech industry: An Asian dragon is growing 5Health News:China's biotech industry: An Asian dragon is growing 6Health News:China's biotech industry: An Asian dragon is growing 7Health News:EggFusion Helps Retailers Address Consumers' Food Safety Concerns 2Health News:EggFusion Helps Retailers Address Consumers' Food Safety Concerns 3Health News:More sun exposure may be good for some people 2Health News:More sun exposure may be good for some people 3Health News:Study Casts Doubt on Vaccine-Autism Link 2Health News:Study Casts Doubt on Vaccine-Autism Link 3
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
(Date:10/17/2014)... October 17, 2014 Investor-Edge has ... (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ... research on these five companies can be accessed at: ... Thursday, October 16, 2014, ended on a mixed note ...
(Date:10/17/2014)... Wash. , Oct. 17, 2014  Talyst, a ... the 2014 LeadingAge Annual Meeting in Nashville, ... InSite System, the market leading solution for onsite, remote ... long term care facilities to safely and securely dispense ... time to first dose, helps ensure that the correct ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
... will evaluate effects of otelixizumab, an investigational anti-CD3 monoclonal antibody, ... ... secretion, CAMBRIDGE, Mass., April 9, 2008 /PRNewswire/ - ... novel,therapies for immune-mediated diseases, today announced that it is,proceeding toward the ...
... Nektar,Therapeutics (Nasdaq: NKTR ) announced today that ... inhaled insulin programs as a,result of new data analysis ... in the number of new cases of lung cancer ... control group. All,new incidences of lung cancer were in ...
Cached Medicine Technology:Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 2Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 3Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 4Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients 2Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients 3
... Ultrasonix ES500 system is an innovative, ... that provides excellent clinical performance. The ... processing of the ES500 system deliver ... and every system offers a full ...
Protects the eye during or after surgery or trauma...
... designed specifically for posteror ... aspirate fluid from subretinal ... provide atraumatic entry through ... or holes. 6mm flexible ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
Medicine Products: